Mark Emberton
Mark Emberton
Professor of Interventional Oncology, University College London, UK
Verified email at
Cited by
Cited by
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
HU Ahmed, AES Bosaily, LC Brown, R Gabe, R Kaplan, MK Parmar, ...
The Lancet 389 (10071), 815-822, 2017
MRI-targeted or standard biopsy for prostate-cancer diagnosis
V Kasivisvanathan, AS Rannikko, M Borghi, V Panebianco, LA Mynderse, ...
New England Journal of Medicine 378 (19), 1767-1777, 2018
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction
M Oelke, A Bachmann, A Descazeaud, M Emberton, S Gravas, MC Michel, ...
European urology 64 (1), 118-140, 2013
Systematic review of complications of prostate biopsy
S Loeb, A Vellekoop, HU Ahmed, J Catto, M Emberton, R Nam, ...
European urology 64 (6), 876-892, 2013
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)
S Madersbacher, G Alivizatos, J Nordling, CR Sanz, M Emberton, ...
European urology 46 (5), 547-554, 2004
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting
L Dickinson, HU Ahmed, C Allen, JO Barentsz, B Carey, JJ Futterer, ...
European urology 59 (4), 477-494, 2011
Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature
JJ Fütterer, A Briganti, P De Visschere, M Emberton, G Giannarini, ...
European urology 68 (6), 1045-1053, 2015
Image-guided prostate biopsy using magnetic resonance imaging–derived targets: a systematic review
CM Moore, NL Robertson, N Arsanious, T Middleton, A Villers, L Klotz, ...
European urology 63 (1), 125-140, 2013
Detection of clinically significant prostate cancer using magnetic resonance imaging–ultrasound fusion targeted biopsy: a systematic review
M Valerio, I Donaldson, M Emberton, B Ehdaie, BA Hadaschik, LS Marks, ...
European urology 68 (1), 8-19, 2015
How good is MRI at detecting and characterising cancer within the prostate?
APS Kirkham, M Emberton, C Allen
European urology 50 (6), 1163-1175, 2006
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group
CM Moore, V Kasivisvanathan, S Eggener, M Emberton, JJ Fütterer, ...
European urology 64 (4), 544-552, 2013
EAU Guidelines on benign prostatic hyperplasia (BPH)
JJ de la Rosette, G Alivizatos, S Madersbacher, M Perachino, D Thomas, ...
European urology 40 (3), 256-263, 2001
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
HU Ahmed, RG Hindley, L Dickinson, A Freeman, AP Kirkham, M Sahu, ...
The lancet oncology 13 (6), 622-632, 2012
The role of focal therapy in the management of localised prostate cancer: a systematic review
M Valerio, HU Ahmed, M Emberton, N Lawrentschuk, M Lazzeri, ...
European urology 66 (4), 732-751, 2014
Is it time to consider a role for MRI before prostate biopsy?
HU Ahmed, A Kirkham, M Arya, R Illing, A Freeman, C Allen, M Emberton
Nature reviews Clinical oncology 6 (4), 197-206, 2009
Photodynamic therapy for prostate cancer—a review of current status and future promise
CM Moore, D Pendse, M Emberton
Nature clinical practice Urology 6 (1), 18-30, 2009
Benign prostatic hyperplasia: a progressive disease of aging men1
M Emberton, GL Andriole, J De La Rosette, B Djavan, K Hoefner, ...
Urology 61 (2), 267-273, 2003
Characterizing clinically significant prostate cancer using template prostate mapping biopsy
HU Ahmed, Y Hu, T Carter, N Arumainayagam, E Lecornet, A Freeman, ...
The Journal of urology 186 (2), 458-464, 2011
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care
O Ukimura, JA Coleman, A De La Taille, M Emberton, JI Epstein, ...
European urology 63 (2), 214-230, 2013
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised …
AR Azzouzi, S Vincendeau, E Barret, A Cicco, F Kleinclauss, ...
The Lancet Oncology 18 (2), 181-191, 2017
The system can't perform the operation now. Try again later.
Articles 1–20